Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:DTIL NASDAQ:OYST NASDAQ:PSTX NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.52+1.5%$5.12$1.38▼$7.34$144.33M1.44782,229 shs5,365 shsDTILPrecision BioSciences$4.55+1.1%$4.80$3.61▼$10.48$53.63M1.61302,759 shs1,609 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPSTXPoseida Therapeutics$9.50$9.48$2.32▼$9.67$928.85M1.631.12 million shsN/ASLDBSolid Biosciences$5.49-0.1%$5.96$2.41▼$8.10$431.40M2.541.80 million shs17,331 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-0.67%+4.46%-3.89%-6.90%-28.91%DTILPrecision BioSciences-2.39%-9.46%-4.46%-8.16%-56.31%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PSTXPoseida Therapeutics0.00%0.00%0.00%0.00%+209.45%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.52+1.5%$5.12$1.38▼$7.34$144.33M1.44782,229 shs5,365 shsDTILPrecision BioSciences$4.55+1.1%$4.80$3.61▼$10.48$53.63M1.61302,759 shs1,609 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPSTXPoseida Therapeutics$9.50$9.48$2.32▼$9.67$928.85M1.631.12 million shsN/ASLDBSolid Biosciences$5.49-0.1%$5.96$2.41▼$8.10$431.40M2.541.80 million shs17,331 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-0.67%+4.46%-3.89%-6.90%-28.91%DTILPrecision BioSciences-2.39%-9.46%-4.46%-8.16%-56.31%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PSTXPoseida Therapeutics0.00%0.00%0.00%0.00%+209.45%SLDBSolid Biosciences+1.86%+7.02%-10.15%+19.09%-30.77%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.50Moderate Buy$14.50225.84% UpsideDTILPrecision BioSciences 3.00Buy$47.00944.44% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/APSTXPoseida Therapeutics 2.00Hold$9.50N/ASLDBSolid Biosciences 3.09Buy$15.00173.22% UpsideCurrent Analyst Ratings BreakdownLatest PSTX, SLDB, OYST, AGEN, and DTIL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/28/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.008/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.008/12/2025AGENAgenusZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/21/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$16.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M1.37N/AN/A($13.06) per share-0.34DTILPrecision BioSciences$1.26M42.06N/AN/A$6.87 per share0.66OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PSTXPoseida Therapeutics$150.86M6.16N/AN/A$1.08 per share8.80SLDBSolid Biosciences$8.09M52.84N/AN/A$3.43 per share1.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)DTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APSTXPoseida Therapeutics-$123.43M-$0.63N/AN/AN/A-40.28%-72.26%-21.53%N/ASLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest PSTX, SLDB, OYST, AGEN, and DTIL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/11/2025Q2 2025AGENAgenus-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APSTXPoseida TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.060.06DTILPrecision BioSciences0.665.185.18OYSTOyster Point Pharma8.493.353.11PSTXPoseida Therapeutics0.683.203.20SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%DTILPrecision BioSciences37.99%OYSTOyster Point Pharma96.70%PSTXPoseida Therapeutics46.87%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%DTILPrecision BioSciences4.50%OYSTOyster Point Pharma17.90%PSTXPoseida Therapeutics2.90%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44031.86 million30.11 millionOptionableDTILPrecision BioSciences20011.79 million11.32 millionNo DataOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePSTXPoseida Therapeutics26097.77 million94.94 millionOptionableSLDBSolid Biosciences10077.87 million67.26 millionOptionablePSTX, SLDB, OYST, AGEN, and DTIL HeadlinesRecent News About These CompaniesWall Street Zen Downgrades Solid Biosciences (NASDAQ:SLDB) to SellSeptember 15 at 2:43 AM | americanbankingnews.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Lowered by Wall Street ZenSeptember 15 at 2:55 AM | marketbeat.comSiren L.L.C. Has $27.44 Million Holdings in Solid Biosciences Inc. $SLDBSeptember 13 at 3:12 AM | marketbeat.comSolid Biosciences Inc. $SLDB Shares Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Stock Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Has $204,000 Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comBrokerages Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.00September 7, 2025 | americanbankingnews.comEcoR1 Capital LLC Purchases New Stake in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comJump Financial LLC Acquires New Position in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comSolid Biosciences Inc. $SLDB is Bain Capital Life Sciences Investors LLC's 7th Largest PositionSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stake in Solid Biosciences Inc. $SLDBSeptember 5, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRedmile Group LLC Has $7.47 Million Stock Position in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 1,096,442 Shares of Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comBirchview Capital LP Makes New Investment in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Invests $6.08 Million in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDBSeptember 3, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comApis Capital Advisors LLC Purchases Shares of 110,000 Solid Biosciences Inc. $SLDBSeptember 2, 2025 | marketbeat.comSolid Biosciences to Participate at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comResolute Capital Asset Partners LLC Makes New $555,000 Investment in Solid Biosciences Inc. $SLDBAugust 25, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePSTX, SLDB, OYST, AGEN, and DTIL Company DescriptionsAgenus NASDAQ:AGEN$4.51 +0.07 (+1.46%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Precision BioSciences NASDAQ:DTIL$4.55 +0.05 (+1.11%) As of 09:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Poseida Therapeutics NASDAQ:PSTXPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Solid Biosciences NASDAQ:SLDB$5.49 0.00 (-0.07%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
